Table 1 Socio-demographic and biomarkers data of controls and Long COVID (LC) patients divided into two groups one with highly increased body temperature, lowered SpO2 and high nitro-oxidative stress (LC + O&NS) versus another group with fewer changes in these biomarkers (LC).

From: Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study

Variables

Controls (n = 36)A

Cluster 1 or LC (n = 67)B

Cluster 2: LC + O&NS (n = 51)C

F/ψ/χ2

df

p

Age (years)

30.9 ± 8.3

29.3 ± 7.2

33.1 ± 8.6

3.32

2/151

0.039

BMI (kg/m2)

26.34 ± 3.64

25.60 ± 3.97

26.65 ± 6.20

0.72

2/146

0.487

Sex (Female/Male)

6/30

25/42

8/43

9.02

2

0.012

Education (years)

15.8 ± 1.2C

15.6 ± 1.6C

15.5 ± 1.8A,B

0.37

2/151

0.689

Single/married

22/14

34/33

15/36

9.56

2

0.008

TUD (No/Yes)

20/16

45/22

36/15

2.24

2

0.321

Residency (Urban/Rural)

7/29

7/60

12/39

3.75

2

0.166

Employment (No/Yes)

36

67

51

Vaccination (A/Pf/S)

11/14/11

23/30/14

20/19/12

1.83

4

0.768

Duration of Disease (weeks)

13.8 ± 3.7C

15.8 ± 6.8B

4.16

1/116

0.044

Peak body temperature (°C)

36.5 ± 0.1B,C

38.8 ± .0.1A,C

39.3 ± 0.1A,B

163.99

2/142

<0.001

Lowest SpO2 (%)

96.6 ± 0.6B,C

92.3 ± 0.4A,C

87.5 ± 0.5A,B

70.06

2/142

<0.001

zTO2 index (z scores)

−1.340 ± 0.091B,C

0.143 ± 0.070A,C

0.862 ± 0.079A,B

170.24

2/142

<0.001

Gpx (ng/ml)

23.46 ± 0.97B,C

21.57 ± 0.75A,C

17.97 ± 0.84A,B

9.84

2/142

<0.001

NO (uM)

20.81 ± 1.47C

18.95 ± 1.13C

28.19 ± 1.27A,B

14.99

2/142

<0.001

Protein carbonyl (ng/ml)

11.38 ± 1.15C

10.73 ± 0.89C

14.43 ± 1.00A,B

3.97

2/142

0.021

MPO (ng/ml)

12.87 ± 0.82C

11.25 ± 0.63C

15.84 ± 0.71A,B

11.32

2/142

<0.001

MDA (nM)

1406.9 ± 97.9C

1432.9 ± 75.5C

1843.0 ± 84.6A,B

8.02

2/142

<0.001

AOPP (uM)

4.84 ± 0.38

5.27 ± 0.29

5.87 ± 0.33

2.19

2/142

0.116

TAC (U/ml)

6.23 ± 0.48

5.23 ± 0.37

5.01 ± 0.41

2.09

2/142

0.128

Nitrotyrosine (nM)

33.44 ± 3.20

34.79 ± 2.46

32.72 ± 2.76

0.16

2/142

0.865

Zinc (ppm)

0.785 ± 0.034C

0.772 ± 0.026C

0.657 ± 0.030A,B

5.37

2/142

0.006

OSTOX (z scores)

−0.357 ± 0.131C

−0.512 ± 0.101C

0.882 ± 0.113A,B

45.19

2/142

<0.001

ANTIOX (z scores)

0.521 ± 0.151B,C

0.107 ± 0.116A,C

−0.580 ± 0.130A,B

16.17

2/142

<0.001

OSTOX / ANTIOX (z scores)

−0.575 ± 0.129A

−0.406 ± 0.100A

0.957 ± 0.113A,B

53.62

2/142

<0.001

CRP (mg/L)

5.42 (0.70)B,C

7.83 (0.55)A

9.11 (0.61)A

7.96

2/140

<0.001

Enoxaparin sodium (No/Yes)a

 

61/6

38/13

5.86

1

0.015

Dexamethasone (No/Yes)a

 

54/13

27/24

10.29

1

0.001

Ceftriaxone (No/Yes)a

 

51/16

34/17

1.28

1

0.257

Azithromycine (No/Yes)a

 

31/36

25/26

0.09

1

0.767

Bromhexine (No/Yes)a

 

50/17

26/25

7.06

1

0.008

Levoflaxacin (No/Yes)a

 

61/6

41/10

2.80

1

0.094

Antidepressants (No/Yes)b

 

55/12

35/16

2.90

1

0.089

Chlordiazepoxide (No/Yes)b

 

65/2

45/6

FEPT

1

0.059

Propanolol (No/Yes)b

 

63/4

49/2

0.25

1

0.616

  1. All results are shown as mean (SD) or as ratios. A,B,C Posthoc comparisons among group means. FEPT: Fisher’s Exact Probability test.
  2. BMI: body mass index, TUD: tobacco-use disorder, Vaccination A1,Pf,S: vaccination type either AstraZeneca (A), Pfizer-BioNTech (Pf), or Sinopharm (S).
  3. zTO2 composite score reflecting combined aberrations in body temperature and SpO2, Gpx glutathione peroxidase, NOx nitric oxide, MPO myeloperoxidase, MDA malondialdehyde, AOPP advanced oxidation protein products, TAC total antioxidant capacity.
  4. aTreatments during the acute phase of COVID-19.
  5. bTreatments in Long-COVID.